Hoppensteadt DA - Search Results

1

Blood levels of nitric oxide, C-reactive protein, and tumor necrosis factor-alpha are upregulated in patients with malignancy-associated hypercoagulable state: pathophysiologic implications.

Fareed D, Iqbal O, Tobu M, Hoppensteadt DA, Fareed J. Fareed D, et al. Among authors: hoppensteadt da. Clin Appl Thromb Hemost. 2004 Oct;10(4):357-64. doi: 10.1177/107602960401000408. Clin Appl Thromb Hemost. 2004. PMID: 15497022 Free article.

2

Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation.

Fareed J, Walenga JM, Hoppensteadt DA, Jeske WP, Ahmad S, Lietz H, McKenna R, Messmore HL, Haas S. Fareed J, et al. Among authors: hoppensteadt da. Clin Appl Thromb Hemost. 1999 Oct;5 Suppl 1:S38-44. doi: 10.1177/10760296990050s108. Clin Appl Thromb Hemost. 1999. PMID: 10726035 Free article.

3

Soluble P-selectin in human plasma: effect of anticoagulant matrix and its levels in patients with cardiovascular disorders.

Amin HM, Ahmad S, Walenga JM, Hoppensteadt DA, Leitz H, Fareed J. Amin HM, et al. Among authors: hoppensteadt da. Clin Appl Thromb Hemost. 2000 Apr;6(2):71-6. doi: 10.1177/107602960000600204. Clin Appl Thromb Hemost. 2000. PMID: 10775025 Free article.

4

Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaose phosphate sulfate (PI-88).

Demir M, Iqbal O, Hoppensteadt DA, Piccolo P, Ahmad S, Schultz CL, Linhardt RJ, Fareed J. Demir M, et al. Among authors: hoppensteadt da. Clin Appl Thromb Hemost. 2001 Apr;7(2):131-40. doi: 10.1177/107602960100700210. Clin Appl Thromb Hemost. 2001. PMID: 11292191 Free article.

5

Influence of different anticoagulant agents on fibrinopeptide a generation.

Tobu M, Iqbal O, Messmore HL, Ma Q, Hoppensteadt DA, Fareed J. Tobu M, et al. Among authors: hoppensteadt da. Clin Appl Thromb Hemost. 2003 Oct;9(4):273-92. doi: 10.1177/107602960300900403. Clin Appl Thromb Hemost. 2003. PMID: 14653437 Free article.

6

Comparative tissue factor pathway inhibitor release potential of heparins.

Tobu M, Ma Q, Iqbal O, Schultz C, Jeske W, Hoppensteadt DA, Fareed J. Tobu M, et al. Among authors: hoppensteadt da. Clin Appl Thromb Hemost. 2005 Jan;11(1):37-47. doi: 10.1177/107602960501100104. Clin Appl Thromb Hemost. 2005. PMID: 15678271 Free article.

7

Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin.

Hoppensteadt DA, Walenga JM, Fareed J. Hoppensteadt DA, et al. Semin Thromb Hemost. 1991;17 Suppl 1:60-4. Semin Thromb Hemost. 1991. PMID: 2068572

8

In vitro protamine neutralization profiles of heparins differing in source and molecular weight.

Racanelli A, Hoppensteadt DA, Fareed J. Racanelli A, et al. Among authors: hoppensteadt da. Semin Thromb Hemost. 1989 Oct;15(4):386-9. doi: 10.1055/s-2007-1002735. Semin Thromb Hemost. 1989. PMID: 2554498 No abstract available.

9

Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide.

Callas DD, Hoppensteadt DA, Jeske W, Iqbal O, Bacher P, Ahsan A, Fareed J. Callas DD, et al. Among authors: hoppensteadt da. Semin Thromb Hemost. 1993;19 Suppl 1:49-57. Semin Thromb Hemost. 1993. PMID: 8362269 No abstract available.

10

Current perspectives on low molecular weight heparins.

Fareed J, Hoppensteadt DA, Walenga JM. Fareed J, et al. Among authors: hoppensteadt da. Semin Thromb Hemost. 1993;19 Suppl 1:1-11. Semin Thromb Hemost. 1993. PMID: 8395709 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

121 results

Search Page

Filters